

Financial news for FGEN dated on 2020-06-08: FibroGen Announces New Roxadustat Data Presented At 2020 ERA-EDTA Virtual Congress

Financial news for FGEN dated on 2020-06-08: FibroGen Announces First Patient Enrolled In Pamrevlumab Clinical Trial In Patients Hospitalized In Italy With Severe COVID-19

Financial news for FGEN dated on 2020-05-21: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Financial news for FGEN dated on 2020-05-21: Astellas Pharma And FibroGen Announce European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat

Financial news for FGEN dated on 2020-05-08: SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to \$80

Financial news for FGEN dated on 2020-05-07: FibroGen Q1 EPS \$(0.890) Down From \$(0.530) YoY, Sales \$24.401M Up From \$23.863M YoY

Financial news for FGEN dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for FGEN dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for FGEN dated on 2020-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2020

Financial news for FGEN dated on 2020-05-01: Cowen & Co. Initiates Coverage On FibroGen with Market Perform Rating, Announces Price Target to \$40

Financial news for FGEN dated on 2020-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2020

Financial news for FGEN dated on 2020-04-27: B of A Securities Initiates Coverage On FibroGen with Neutral Rating, Announces Price Target to \$45

Financial news for FGEN dated on 2020-04-20: FibroGen Announces UK Has Held Certain Patents Relating To 'methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors' To Be Invalid; Ruling Does Not Affect Validity Of Patents In Rest Of Europe

Financial news for FGEN dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for FGEN dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for FGEN dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for FGEN dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for FGEN dated on 2020-03-02: FibroGen Q4 EPS \$(1.12) Misses \$(0.59) Estimate, Sales \$7.974M Down From \$108.054M YoY

Financial news for FGEN dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for FGEN dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for FGEN dated on 2020-02-11: FibroGen Reports FDA Accepted New Drug Application for Roxadustat For Treatment Of Anemia Of Chronic Kidney Disease

Financial news for FGEN dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for FGEN dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for FGEN dated on 2020-01-06: FibroGen Announces Enrique Conterno CEO

Financial news for FGEN dated on 2019-12-23: FibroGen Submits New Drug Application for Roxadustat in Patients With Anemia of Chronic Kidney Disease

Financial news for FGEN dated on 2019-12-02: FibroGen Announces Roxadustat Inclusion

in China's National Reimbursement Drug List

Financial news for FGEN dated on 2019-11-29: Fibrogen shares are trading higher after Roxadustat was added to a national insurance list for coverage by China's state-run medical insurance fund.

Financial news for FGEN dated on 2019-11-12: Fibrogen Shares Fall To Session Low, Down 4%; Muddy Waters Research Tweets 'Under-reported deaths in clinical trial - this looks pretty serious (no position)'

Financial news for FGEN dated on 2019-11-12: 58 Biggest Movers From Yesterday

Financial news for FGEN dated on 2019-11-11: FibroGen shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Financial news for FGEN dated on 2019-11-11: FibroGen Q3 EPS \$(0.57) Misses \$(0.55) Estimate, Sales \$33.17M Beat \$31.6M Estimate

Financial news for FGEN dated on 2019-11-11: These Are The Winners Of The Inaugural WeTrader Paper Trading Competition

Financial news for FGEN dated on 2019-11-11: Earnings Scheduled For November 11, 2019

Financial news for FGEN dated on 2019-11-08: FibroGen Shares Resume Trade

Financial news for FGEN dated on 2019-11-08: FibroGen Shares To Resume Trade At 2:30 p.m. ET

Financial news for FGEN dated on 2019-11-08: AstraZeneca Says Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy And No Increased Cardiovascular Risk In Patients With Anemia From Chronic Kidney Disease Versus Comparators

Financial news for FGEN dated on 2019-11-08: FibroGen Shares Halted, News Pending

Financial news for FGEN dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for FGEN dated on 2019-11-07: FibroGen Presents Phase 3 Efficacy And Safety Results For Roxadustat Versus Epoetin Alfa As Treatment Of Anemia In Incident Dialysis Patients With Chronic Kidney Disease

Financial news for FGEN dated on 2019-11-05: 46 Biggest Movers From Yesterday

Financial news for FGEN dated on 2019-11-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for FGEN dated on 2019-11-04: UPDATE: Plainview Says We are short \$FGEN and believe \$FGEN's ASN 2019 pres on Fri Nov 8 will show lead drug roxadustat failed to achieve key endpt of MACE non-inferiority in DD-CKD/NDD-CKD'

Financial news for FGEN dated on 2019-11-04: Plainview Out With Short Report On FibroGen

Financial news for FGEN dated on 2019-10-23: FibroGen Announces First Patient Dosed In LAPIS Phase 3 Clinical Trial Of Pamrevlumab For The Treatment Of Patients With Locally Advanced Pancreatic Cancer

Financial news for FGEN dated on 2019-09-26: Fibrogen Reports Initiation of Phase 2 Trial Of Roxadustat For Patients With Anemia In Cancer After Reciving Chemotherapy

Financial news for FGEN dated on 2019-09-20: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

Financial news for FGEN dated on 2019-09-20: Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

Financial news for FGEN dated on 2019-08-27: Jon Najarian Sees Unusual Options Activity In Freeport-McMoRan And FibroGen

Financial news for FGEN dated on 2019-08-26: Mizuho Maintains Buy on FibroGen, Maintains \$65 Price Target

Financial news for FGEN dated on 2019-08-26: FibroGen Option Alert: Jan 17 \$45 Calls at the Ask: 3950 @ \$5.6 vs 50 OI; Ref=\$43.025

Financial news for FGEN dated on 2019-08-26: FibroGen Option Alert: Jan 17 \$45 Calls Sweep (2) near the Ask: 4000 @ \$5.6 vs 50 OI; Ref=\$43.1

Financial news for FGEN dated on 2019-08-26: FibroGen Announces the Death of its CEO,

James Schoeneck Named Interim CEO

Financial news for FGEN dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for FGEN dated on 2019-08-21: FibroGen's Roxadustat Approved In China For Treatment Of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis

Financial news for FGEN dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for FGEN dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for FGEN dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for FGEN dated on 2019-08-09: 52 Stocks Moving In Friday's Pre-Market Session

Financial news for FGEN dated on 2019-08-08: FibroGen Q2 EPS \$1.26 Beats \$(0.51) Estimate, Sales \$191.566M Beat \$29.03M Estimate

Financial news for FGEN dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for FGEN dated on 2019-07-22: FibroGen Announces First Patient Dosed In ZEPHYRUS Phase 3 Clinical Trial Of Pamrevlumab For Treatment Of Patients With Idiopathic Pulmonary Fibrosis

Financial news for FGEN dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for FGEN dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for FGEN dated on 2019-06-28: FibroGen To Present Interim Phase 2 Data On Pamrevlumab In Subjects With Duchenne Muscular Dystrophy At Parent Project Muscular Dystrophy Conference Fri., Jun. 28, 2019

Financial news for FGEN dated on 2019-05-29: Goldman Sachs Assumes FibroGen at Neutral, Announces Price Target \$45

Financial news for FGEN dated on 2019-05-13: 72 Biggest Movers From Friday

Financial news for FGEN dated on 2019-05-10: 62 Stocks Moving In Friday's Mid-Day Session

Financial news for FGEN dated on 2019-05-10: FibroGen shares are trading lower following results from a study of roxadustat. A STAT News article suggested the company's "obtuse disclosure" raised concerns about heart safety with the candidate.

Financial news for FGEN dated on 2019-05-10: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for FGEN dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for FGEN dated on 2019-05-10: 'Fibrogen's obtuse disclosures about anemia pill raise concerns about heart safety, putting approval at risk' -STAT News

Financial news for FGEN dated on 2019-05-10: William Blair Downgrades FibroGen, Inc - Common Stock to Market Perform

Financial news for FGEN dated on 2019-05-09: FibroGen Q1 EPS \$(0.53) Beats \$(0.67) Estimate, Sales \$23.863M Beat \$17.88M Estimate

Financial news for FGEN dated on 2019-05-09: FibroGen Announces 'Positive' Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

Financial news for FGEN dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for FGEN dated on 2019-04-15: FibroGen Receives Orphan Drug Designation from the US FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

Financial news for FGEN dated on 2019-04-12: Benzinga's Top Upgrades, Downgrades For April 12, 2019

Financial news for FGEN dated on 2019-04-12: PiperJaffray Initiates Coverage On FibroGen with Neutral Rating, Announces \$65 Price Target

Financial news for FGEN dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for FGEN dated on 2019-02-27: FibroGen Q4 EPS \$0.23, Sales \$108.05M Beat \$72.15M Estimate

Financial news for FGEN dated on 2019-02-27: FibroGen Q4 EPS \$0.23 Beats \$(0.10) Estimate, Sales \$108.05M Beat \$72.15M Estimate

Financial news for FGEN dated on 2019-02-11: Stifel Nicolaus Reinstates Buy on FibroGen, Announces \$71 Target

Financial news for FGEN dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for FGEN dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for FGEN dated on 2018-12-20: 46 Stocks Moving In Thursday's Mid-Day Session

Financial news for FGEN dated on 2018-12-20: FibroGen shares are trading up 7.5% after the company announced all three Phase 3 Roxadustat trials met primary efficacy endpoints.

Financial news for FGEN dated on 2018-12-20: FibroGen Announces All Three Phase 3 Trials Of Roxadustat For Chronic Kidney Disease Met Primary Efficacy Endpoints

Financial news for FGEN dated on 2018-12-19: FibroGen shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and announced a price target of \$71.

Financial news for FGEN dated on 2018-12-19: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for FGEN dated on 2018-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2018

Financial news for FGEN dated on 2018-12-19: Citigroup Upgrades FibroGen to Buy, Announces \$71 Price Target

Financial news for FGEN dated on 2018-12-18: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for FGEN dated on 2018-12-18: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for FGEN dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for FGEN dated on 2018-12-17: FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

Financial news for FGEN dated on 2018-12-14: FibroGen Option Alert: Mar 15 \$45 Calls Sweep (31) near the Ask: 558 @ \$5.281 vs 126 OI; Ref=\$40.0

Financial news for FGEN dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for FGEN dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for FGEN dated on 2018-11-08: FibroGen Q3 EPS \$(0.50) Down From \$(0.32) YoY, Sales \$29.03M Down From \$40.55M YoY

Financial news for FGEN dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for FGEN dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2,

Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for FGEN dated on 2018-10-26: FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at ASN Kidney Week 2018 Annual Meeting

Financial news for FGEN dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for FGEN dated on 2018-10-01: Astellas Pharma, FibroGen Report Astellas Submitted New Drug Application For Marketing Approval In Japan Of Roxadustat For Treatment Of Anemia Associated With Chronic Kidney Disease In Patients On Dialysis

Financial news for FGEN dated on 2018-09-12: Fibrogen 8-K Shows Co. Received Fast Track Designation For Pamrevlumab For Treatment Of Idiopathic Pulmonary Fibrosis

Financial news for FGEN dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for FGEN dated on 2018-08-07: FibroGen Q2 EPS \$(0.28) May Not Compare To \$(0.59) Estimate, Sales \$43.95M May Not Compare To \$27.74M Estimate

Financial news for FGEN dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for FGEN dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for FGEN dated on 2018-06-22: Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap

Financial news for FGEN dated on 2018-06-07: FibroGen Announces Completion Of Enrollment In U.S. Phase 3 Clinical Program For Roxadustat In Anemia Associated With Chronic Kidney Disease

Financial news for FGEN dated on 2018-06-04: FibroGen Presents Positive Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at #ASCO2018

Financial news for FGEN dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for FGEN dated on 2018-05-21: FibroGen Announces PRIASE Phase 2b Study Data Presented At American Thoracic Society 2018 Event

Financial news for FGEN dated on 2018-05-15: FibroGen Upgraded By Mizuho On Continued R&D Progress

Financial news for FGEN dated on 2018-05-15: Benzinga's Top Upgrades, Downgrades For May 15, 2018

Financial news for FGEN dated on 2018-05-15: Mizuho Upgrades FibroGen to Buy

Financial news for FGEN dated on 2018-05-09: FibroGen Q1 EPS \$(0.50) Beats \$(0.51) Estimate, Sales \$31.925M Beat \$27.15M Estimate

Financial news for FGEN dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for FGEN dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for FGEN dated on 2018-03-01: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab

Financial news for FGEN dated on 2018-02-27: FibroGen Reports Q4 EPS \$(0.27) vs \$(0.29) Est., Sales \$42.509M vs \$49.8M Est.

Financial news for FGEN dated on 2018-02-27: FibroGen Q4 Earnings Outlook

Financial news for FGEN dated on 2017-11-08: FibroGen Reports Q3 EPS \$(0.50) vs. \$(0.38) In Same Qtr. Last Year, Sales \$27.3M vs. \$30.1M YoY

Financial news for FGEN dated on 2017-10-18: UPDATE: FibroGen Reports NDA Submission Triggers \$15M Milestone Payment To FibroGen By AstraZeneca

Financial news for FGEN dated on 2017-10-18: FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application

Financial news for FGEN dated on 2017-10-16: The Week Ahead: Earnings, Earnings, And More Earnings

Financial news for FGEN dated on 2017-10-16: Secondary Offering Lockup Expirations Today for Performance Food Group, Fibrogen, and AZUL

Financial news for FGEN dated on 2017-10-11: Lightning Round: Jim Cramer Gives His Opinion On Kratos Defense & Security Solutions, Nike And More

Financial news for FGEN dated on 2017-10-05: 20 Biggest Mid-Day Losers For Thursday

Financial news for FGEN dated on 2017-10-05: Benzinga's Top Upgrades, Downgrades For October 5, 2017

Financial news for FGEN dated on 2017-10-05: Mizuho Initiates Coverage On FibroGen with Neutral Rating, Announces \$61.00 Price Target

Financial news for FGEN dated on 2017-09-13: Fibrogen Phase 2b Study of Pamrevlumab Met Primary Endpoint

Financial news for FGEN dated on 2017-08-16: FibroGen Prices 8M Share Offering @\$40.75/Share

Financial news for FGEN dated on 2017-08-14: FibroGen Announces \$300M Follow-On Offering Common Stock

Financial news for FGEN dated on 2017-08-14: Fibrogen Files to Sell Up to \$300M of Common Stock

Financial news for FGEN dated on 2017-08-10: Morgan Stanley Expects Galapagos Shares To Rise 10%

Financial news for FGEN dated on 2017-08-08: Mid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide

Financial news for FGEN dated on 2017-08-08: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for FGEN dated on 2017-08-08: Mid-Day Market Update: Stocks Turn Higher; Depomed Shares Plummet

Financial news for FGEN dated on 2017-08-08: Mid-Morning Market Update: Markets Edge Lower; CVS Health Profit Tops Expectations

Financial news for FGEN dated on 2017-08-08: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for FGEN dated on 2017-08-07: FibroGen Reports Q2 Loss/Share \$(0.48) vs. \$(0.47) Est., Sales \$29M vs. \$34.32M Est.

Financial news for FGEN dated on 2017-07-21: Goldman Sachs Downgrades FibroGen to Neutral

Financial news for FGEN dated on 2017-07-11: Jefferies Initiates Coverage On FibroGen with Buy Rating, Announces \$50.00 Price Target

Financial news for FGEN dated on 2017-06-22: FibroGen Granted FDA Orphan Drug Designation for Pamrevlumab in Treatment of Pancreatic Cancer GLN

Financial news for FGEN dated on 2017-06-21: FDA Site Shows Orphan Drug Designation Update For FibroGen's Treatment For Pancreatic Cancer, Pamrevlumab

Financial news for FGEN dated on 2017-05-09: FibroGen Reports Q1 EPS \$(0.52) vs \$(0.49) Est., Sales \$26.891M vs \$28.14M Est.

Financial news for FGEN dated on 2017-04-06: FibroGen Prices Follow-On Offering Of 5.22M Shares At \$22.95/Share

Financial news for FGEN dated on 2017-03-31: FibroGen Reports China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat

Financial news for FGEN dated on 2017-03-30: UPDATE: FibroGen Says 'Findings are Consistent with China Phase 3 Trials Results, and Support China NDA Submission'

Financial news for FGEN dated on 2017-03-30: FibroGen Reports Results from 2 China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Financial news for FGEN dated on 2017-03-01: Fibrogen Reports FY16 EPS \$(0.98) vs \$(1.42) in Same Qtr. Last Year, Sales \$179.577M

Financial news for FGEN dated on 2017-03-01: Filing form Fibrogen Shows Registration for Mixed Securities Shelf Offering

Financial news for FGEN dated on 2017-02-03: FibroGen Reports Publication of FG-3019 Data in Pancreatic Cancer Which Showed Safety, Improved Survival Outcomes in Combo with Chemo

Financial news for FGEN dated on 2017-01-30: 20 Biggest Mid-Day Losers For Monday

Financial news for FGEN dated on 2017-01-30: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for FGEN dated on 2017-01-30: FibroGen Reports FG-4592 Met Primary Endpoints in 2 Phase 3 Anemia Studies in China

Financial news for FGEN dated on 2017-01-13: 7 Biotech Catalysts Remaining In January

Financial news for FGEN dated on 2016-11-08: Fibrogen Reports Q3 EPS \$(0.38) vs \$(0.60) Est., \$(0.74) in Same Qtr. Last Year

Financial news for FGEN dated on 2016-09-19: 10 Stocks Which Rallied Three Days On Increasing Volume

Financial news for FGEN dated on 2016-08-08: After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%

Financial news for FGEN dated on 2016-08-08: FibroGen Reports Q2 EPS \$0.39 vs. Est. \$0.36, Rev. \$89.28M vs. Est. \$78.5M

Financial news for FGEN dated on 2016-07-08: FibroGen Receives \$62M License Payment from AstraZeneca

Financial news for FGEN dated on 2016-06-09: FibroGen Announces \$10M Milestone Payment

Financial news for FGEN dated on 2016-05-09: FibroGen Reports Q1 EPS \$(0.45) Vs Est \$(0.56), Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data

Financial news for FGEN dated on 2016-04-21: FibroGen Announces Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis

Financial news for FGEN dated on 2016-03-11: FibroGen Offers Phase 2 Results Supporting Potential FG-3019 to Treat Patients with Idiopathic Pulmonary Fibrosis

Financial news for FGEN dated on 2016-02-16: Fibrogen Gains On Strong Phase 2 Data

Financial news for FGEN dated on 2016-02-16: UPDATE: Fibrogen Says Roxadustat Well Tolerated in Study Population; Treatment-Emergent Adverse Events Reported in 63% of All Patients in Safety Population

Financial news for FGEN dated on 2016-02-16: FibroGen Published Data Shows Roxadustat Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Disease

Financial news for FGEN dated on 2016-02-11: Benzinga's Top Upgrades

Financial news for FGEN dated on 2016-02-11: Credit Suisse Upgrades FibroGen to Outperform, Raises PT to \$40.00

Financial news for FGEN dated on 2016-01-21: Credit Suisse Initiates On Smid-Cap Biotechs, Reveals Favorite Stock Picks

Financial news for FGEN dated on 2016-01-20: Credit Suisse Initiates Coverage on FibroGen at Neutral, Announces \$29.00 PT

Financial news for FGEN dated on 2015-12-04: Citigroup Initiates Coverage on FibroGen at Buy, Announces \$40.00 PT

Financial news for FGEN dated on 2015-11-12: FibroGen Reports Q3 EPS (\$0.74) vs. Est. (\$0.59), Rev. \$19.538M vs. Est. \$31.94M

Financial news for FGEN dated on 2015-08-13: Willdan Group Reports Q2 EPS \$0.20 vs Est \$0.25, Sales \$36.8M Vs Est \$35.60M

Financial news for FGEN dated on 2015-08-13: FibroGen Reports Q2 EPS \$0.83 Vs Est \$0.73, Sales \$120.6M Vs Est \$111.75M

Financial news for FGEN dated on 2015-08-13: Why Akebia Therapeutics Is Worth \$10 Per Share, But Needs More Visibility

Financial news for FGEN dated on 2015-08-10: ARIAD Reports First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)

Financial news for FGEN dated on 2015-07-29: Benzinga's Top Initiations

Financial news for FGEN dated on 2015-07-29: Citigroup Initiates Coverage on FibroGen at Buy, Announces \$37.00 PT

Financial news for FGEN dated on 2015-07-27: FibroGen Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy

Financial news for FGEN dated on 2015-07-20: Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs

Financial news for FGEN dated on 2015-06-29: FibroGen Announces \$120M Contingent License Payment from AstraZeneca

Financial news for FGEN dated on 2015-06-23: Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers

Financial news for FGEN dated on 2015-06-22: Morning Market Gainers

Financial news for FGEN dated on 2015-06-22: Benzinga's Top #PreMarket Gainers

Financial news for FGEN dated on 2015-05-12: FibroGen Reports Q1 Loss \$0.78 Vs Est Loss \$0.52 May Not Compare, Sales \$16.3M

Financial news for FGEN dated on 2015-05-12: FibroGen Reports Q1 EPS \$(0.78) vs. Est. \$(0.52), Rev. \$16.29M vs. Est. \$34M; Estimates May Not Compare

Financial news for FGEN dated on 2015-03-26: FibroGen Reports Q4 EPS \$(1.01) vs. Est. \$(0.90)

Financial news for FGEN dated on 2015-01-09: Goldman Sachs Downgrades FibroGen to Neutral, Maintains \$32.00 PT

Financial news for FGEN dated on 2015-01-06: Stocks Hitting 52-Week Highs

Financial news for FGEN dated on 2014-12-17: Stocks Hitting 52-Week Highs

Financial news for FGEN dated on 2014-12-09: Fibronet Initiated Buy At Stifel With A Price Target Of \$39.00

Financial news for FGEN dated on 2014-12-09: Fibronet Initiated Outperform At RBC Capital With A Price Target Of \$38.00

Financial news for FGEN dated on 2014-11-14: Shares of FibroGen Open for Trade at \$23/Share, IPO Priced at \$18

Financial news for FGEN dated on 2014-11-14: FibroGen Shares Remain in Pre-Launch Status Pending Added Price Discovery

Financial news for FGEN dated on 2014-11-14: Expected IPOs For November 14

Financial news for FGEN dated on 2014-11-14: US Stock Futures Flat Ahead Of Retail Sales, Consumer Sentiment Data

Financial news for FGEN dated on 2014-11-14: FibroGen Prices 8.1M Share IPO @\$18.00/Share